{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:54:55Z","timestamp":1781636095567,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Outcomes of allogeneic stem cell transplantation in older patients with acute myeloid leukemia (AML) have been unsatisfactory. At our center, cord blood transplantation (CBT) using FM80TBI has been implemented in older patients or those with comorbidities. We conducted a retrospective single-center study to evaluate transplantation outcomes in patients with AML who underwent CBT following FM80TBI. The FM80TBI regimen consisted of fludarabine (125 or 150\u00a0mg\/m\u00b2), melphalan (80\u00a0mg\/m\u00b2), and total-body irradiation (4\u00a0Gy). This study included 58 patients. The median follow-up period was 38 months. The median age at transplant was 67 (52\u201373) years. At the time of CBT, 39.7% of all patients having an Eastern Cooperative Oncology Group performance status of \u2264\u20092 did not achieve complete remission (CR), 25.9% had adverse cytogenetic risk, and 53.4% were positive for Wilms tumor gene-1 messenger RNA in peripheral blood. Neutrophil engraftment by day 42 was achieved in 87.9% of patients. The 3-year overall survival (OS) was 67.1%, the 3-year non-relapse mortality was 14.4%, and the 3-year cumulative incidence of relapse was 20.0%. Patients with CR status at the time of CBT had significantly better 3-year OS than those with non-CR status (86.8% vs. 42.4%,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05). The cumulative incidences of Grade II\u2013IV acute graft-versus-host disease (GVHD) at day 100 and chronic GVHD at 2 years were 29.4% and 15.0%, respectively. Although this was a single-center retrospective study, the outcomes of CBT for older patients with AML or those with comorbidities following FM80TBI were favorable.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-06888-3","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T04:23:43Z","timestamp":1771215823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcome of initial cord blood transplantation with FM80TBI as conditioning regimen for acute myeloid leukemia"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9239-7516","authenticated-orcid":false,"given":"Masahiro","family":"Akimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumichi","family":"Fujimaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yotaro","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuku","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nodoka","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuki","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"6888_CR1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM (2019) Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev 36:70\u201387. https:\/\/doi.org\/10.1016\/j.blre.2019.04.005","journal-title":"Blood Rev"},{"key":"6888_CR2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1182\/blood-2013-02-453175","volume":"122","author":"KK Ballen","year":"2013","unstructured":"Ballen KK, Gluckman E, Broxmeyer HE (2013) Umbilical cord blood transplantation: the first 25 years and beyond. Blood 122:491\u2013498. https:\/\/doi.org\/10.1182\/blood-2013-02-453175","journal-title":"Blood"},{"key":"6888_CR3","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1200\/JCO.2005.05.694","volume":"23","author":"H Wallen","year":"2005","unstructured":"Wallen H, Gooley TA, Deeg HJ et al (2005) Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 23:3439\u20133446. https:\/\/doi.org\/10.1200\/JCO.2005.05.694","journal-title":"J Clin Oncol"},{"key":"6888_CR4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.bbmt.2015.10.019","volume":"22","author":"A Rashidi","year":"2016","unstructured":"Rashidi A, Ebadi M, Colditz GA, DiPersio JF (2016) Outcomes of allogeneic stem cell transplantation in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis. Biol Blood Marrow Transpl 22:651\u2013657. https:\/\/doi.org\/10.1016\/j.bbmt.2015.10.019","journal-title":"Biol Blood Marrow Transpl"},{"key":"6888_CR5","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s12185-021-03233-4","volume":"115","author":"Y Yamada","year":"2022","unstructured":"Yamada Y, Ikegawa S, Najima Y et al (2022) Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine\/low-dose Melphalan plus 4 Gy TBI versus fludarabine\/ Busulfan plus 4 Gy TBI. Int J Hematol 115:244\u2013254. https:\/\/doi.org\/10.1007\/s12185-021-03233-4","journal-title":"Int J Hematol"},{"key":"6888_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1182\/blood.v97.3.631","volume":"97","author":"S Giralt","year":"2001","unstructured":"Giralt S, Thall PF, Khouri I et al (2001) Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97:631\u2013637. https:\/\/doi.org\/10.1182\/blood.v97.3.631","journal-title":"Blood"},{"key":"6888_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/ajh.24613","volume":"92","author":"H Nakasone","year":"2017","unstructured":"Nakasone H, Fuji S, Yakushijin K et al (2017) Impact of total body irradiation on successful neutrophil engraftment in unrelated bone marrow or cord blood transplantation. Am J Hematol 92:171\u2013178. https:\/\/doi.org\/10.1002\/ajh.24613","journal-title":"Am J Hematol"},{"key":"6888_CR8","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/ajh.27172","volume":"99","author":"N Kurita","year":"2024","unstructured":"Kurita N, Imahashi N, Chiba S et al (2024) Comparison of fludarabine-based conditioning regimens in adult cord blood transplantation for myeloid malignancy: a retrospective, registry-based study. Am J Hematol 99:236\u2013244. https:\/\/doi.org\/10.1002\/ajh.27172","journal-title":"Am J Hematol"},{"key":"6888_CR9","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1038\/sj.leu.2404886","volume":"21","author":"A Shimoni","year":"2007","unstructured":"Shimoni A, Hardan I, Shem-Tov N et al (2007) Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine\/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine\/busulfan. Leukemia 21:2109\u20132116. https:\/\/doi.org\/10.1038\/sj.leu.2404886","journal-title":"Leukemia"},{"key":"6888_CR10","doi-asserted-by":"publisher","first-page":"104746","DOI":"10.1016\/j.exphem.2025.104746","volume":"144","author":"T Tachibana","year":"2025","unstructured":"Tachibana T, Izumi A, Arai S et al (2025) Preconditioning intervention prior to allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia. Exp Hematol 144:104746. https:\/\/doi.org\/10.1016\/j.exphem.2025.104746","journal-title":"Exp Hematol"},{"key":"6888_CR11","first-page":"1279","volume":"46","author":"S Miyawaki","year":"2005","unstructured":"Miyawaki S, Emi N, Mitani K et al (2005) Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan. Rinsho Ketsueki 46:1279\u20131287","journal-title":"Rinsho Ketsueki"},{"key":"6888_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s12185-015-1882-1","volume":"103","author":"K Kitamura","year":"2016","unstructured":"Kitamura K, Nishiyama T, Ishiyama K et al (2016) Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood. Int J Hematol 103:53\u201362. https:\/\/doi.org\/10.1007\/s12185-015-1882-1","journal-title":"Int J Hematol"},{"key":"6888_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"key":"6888_CR14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M et al (2015) National institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-Host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transpl 21:389\u2013401e1. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001","journal-title":"Biol Blood Marrow Transpl"},{"key":"6888_CR15","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P et al (1995) 1994 consensus conference on acute GVHD grading. Bone Marrow Transpl 15:825\u2013828","journal-title":"Bone Marrow Transpl"},{"key":"6888_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transpl"},{"key":"6888_CR17","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1158\/1078-0432.CCR-23-3673","volume":"30","author":"A Bazarbachi","year":"2024","unstructured":"Bazarbachi A, Labopin M, Moukalled N et al (2024) Improvements in posttransplant outcomes over two decades in older patients with acute myeloid leukemia in the EBMT ALWP study. Clin Cancer Res 30:1778\u20131787. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3673","journal-title":"Clin Cancer Res"},{"key":"6888_CR18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s12185-022-03486-7","volume":"117","author":"M Yanada","year":"2023","unstructured":"Yanada M, Yamasaki S, Konuma T et al (2023) Age and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia. Int J Hematol 117:398\u2013408. https:\/\/doi.org\/10.1007\/s12185-022-03486-7","journal-title":"Int J Hematol"},{"key":"6888_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3349\/ymj.2022.0331","volume":"64","author":"YS Ji","year":"2023","unstructured":"Ji YS, Ahn JS, Yun J et al (2023) Clinical experience of allogeneic hematopoietic stem cell transplantation in elderly patients aged 60 years and older in South Korea. Yonsei Med J 64:123\u2013132. https:\/\/doi.org\/10.3349\/ymj.2022.0331","journal-title":"Yonsei Med J"},{"key":"6888_CR20","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s41409-022-01650-5","volume":"57","author":"JE Maakaron","year":"2022","unstructured":"Maakaron JE, Zhang MJ, Chen K et al (2022) Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis. Bone Marrow Transpl 57:911\u2013917. https:\/\/doi.org\/10.1038\/s41409-022-01650-5","journal-title":"Bone Marrow Transpl"},{"key":"6888_CR21","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.bbmt.2008.03.003","volume":"14","author":"N Uchida","year":"2008","unstructured":"Uchida N, Wake A, Takagi S et al (2008) Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases. Biol Blood Marrow Transpl 14:583\u2013590. https:\/\/doi.org\/10.1016\/j.bbmt.2008.03.003","journal-title":"Biol Blood Marrow Transpl"},{"key":"6888_CR22","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00277-021-04464-5","volume":"100","author":"M Isobe","year":"2021","unstructured":"Isobe M, Konuma T, Masuko M et al (2021) Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan. Ann Hematol 100:1849\u20131861. https:\/\/doi.org\/10.1007\/s00277-021-04464-5","journal-title":"Ann Hematol"},{"key":"6888_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41408-022-00678-6","volume":"12","author":"T Konuma","year":"2022","unstructured":"Konuma T, Mizuno S, Kondo T et al (2022) Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia. Blood Cancer J 12:81. https:\/\/doi.org\/10.1038\/s41408-022-00678-6","journal-title":"Blood Cancer J"},{"key":"6888_CR24","doi-asserted-by":"publisher","first-page":"1090e1","DOI":"10.1016\/j.jtct.2024.08.007","volume":"30","author":"O Albanyan","year":"2024","unstructured":"Albanyan O, Elmariah H, Kalos D et al (2024) Melphalan dose in combination with fludarabine affects GI toxicity and GVHD after allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndromes. Transpl Cell Ther 30:1090e1\u20131090e10. https:\/\/doi.org\/10.1016\/j.jtct.2024.08.007","journal-title":"Transpl Cell Ther"},{"key":"6888_CR25","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1007\/s00277-022-04990-w","volume":"101","author":"K Sakatoku","year":"2022","unstructured":"Sakatoku K, Kim SW, Okamura H et al (2022) Improved survival after single-unit cord blood transplantation using fludarabine and Melphalan-based reduced-intensity conditioning for malignant lymphoma: impact of Melphalan dose and graft-versus-host disease prophylaxis with mycophenolate mofetil. Ann Hematol 101:2743\u20132757. https:\/\/doi.org\/10.1007\/s00277-022-04990-w","journal-title":"Ann Hematol"},{"key":"6888_CR26","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.bbmt.2012.08.011","volume":"19","author":"UD Bayraktar","year":"2013","unstructured":"Bayraktar UD, Bashir Q, Qazilbash M, Champlin RE, Ciurea SO (2013) Fifty years of Melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 19:344\u2013356. https:\/\/doi.org\/10.1016\/j.bbmt.2012.08.011","journal-title":"Biol Blood Marrow Transpl"},{"key":"6888_CR27","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","volume":"28","author":"M Duval","year":"2010","unstructured":"Duval M, Klein JP, He W et al (2010) Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 28:3730\u20133738. https:\/\/doi.org\/10.1200\/JCO.2010.28.8852","journal-title":"J Clin Oncol"},{"key":"6888_CR28","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/s41409-017-0028-x","volume":"53","author":"H Ogawa","year":"2018","unstructured":"Ogawa H, Ikegame K, Daimon T et al (2018) Impact of pretransplant leukemic blast% in bone marrow and peripheral blood on transplantation outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in non-CR. Bone Marrow Transpl 53:478\u2013482. https:\/\/doi.org\/10.1038\/s41409-017-0028-x","journal-title":"Bone Marrow Transpl"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06888-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06888-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06888-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:17:51Z","timestamp":1781633871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06888-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6888"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06888-3","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"5 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}}],"article-number":"118"}}